Loading
companiesCompany
Veru
Veru is a Miami company whose oncology programmes were the selective androgen receptor modulator enobosarm for AR-positive, ER-positive breast cancer and the microtubule disruptor sabizabulin for prostate cancer, which was halted in 2022.
Also called: Veru Inc.Veru Pharma
Overview
Veru Inc., listed on Nasdaq, moved from sexual health products into oncology and metabolic disease. Sabizabulin, an oral microtubule disruptor, was tested in metastatic castration-resistant prostate cancer (VERACITY) until the trial was stopped in 2022 and then, controversially, in COVID-19. Enobosarm, a selective androgen receptor modulator, was studied in androgen receptor-positive, oestrogen receptor-positive metastatic breast cancer (ARTEST, ENABLAR-2) before the company redirected it to preserving muscle during weight-loss therapy. It appears on OnCo as a lead sponsor of phase 3 cancer trials on ClinicalTrials.gov.
Similar pages
- TreatmentFluoxymesterone
Shares Androgen receptor, HR-positive / HER2-negative breast cancer.
- Target5-alpha-reductase type 2 (SRD5A2)
Shares Androgen receptor, Prostate cancer.
- PersonEric J. Small
Shares Androgen receptor, Prostate cancer.
- TreatmentAZD9750
Shares Androgen receptor, Prostate cancer.
- TreatmentQLH12016
Shares Androgen receptor, Prostate cancer.
- TreatmentEP0062
Shares Androgen receptor, HR-positive / HER2-negative breast cancer.
- PersonMatthew R. Smith
Shares Androgen receptor, Prostate cancer.
- TreatmentBMS-986365
Shares Androgen receptor, Prostate cancer.